Toripalimab plus initial chemotherapy prolongs PFS, OS in non-small cell lung cancer

The addition of toripalimab to first-line chemotherapy prolonged PFS and OS among patients with advanced non-small cell lung cancer without EGFR/ALK mutations, according to study results.
Results of the phase 3 CHOICE-01 trial, presented during a ASCO Plenary Series session, specifically showed PFS and OS improvement with the combination among patients with mutations in the FA-PI3K-Akt pathway.
“These results support toripalimab [Junshi Biosciences] combined with chemotherapy as a first-line treatment option for patients with advanced NSCLC without driver mutations,” Jie Wang, MD,

The addition of toripalimab to first-line chemotherapy prolonged PFS and OS among patients with advanced non-small cell lung cancer without EGFR/ALK mutations, according to study results.
Results of the phase 3 CHOICE-01 trial, presented during a ASCO Plenary Series session, specifically showed PFS and OS improvement with the combination among patients with mutations in the FA-PI3K-Akt pathway.
“These results support toripalimab [Junshi Biosciences] combined with chemotherapy as a first-line treatment option for patients with advanced NSCLC without driver mutations,” Jie Wang, MD,